Wapnick Pamela 4
4 · Metagenomi Therapeutics, Inc. · Filed Apr 3, 2026
Research Summary
AI-generated summary of this filing
Metagenomi (MGX) CFO Pamela Wapnick Receives 168,000-Share Award
What Happened Pamela Wapnick, Chief Financial Officer of Metagenomi Therapeutics, Inc. (MGX), received equity awards reported on a Form 4 covering transactions dated April 1, 2026. The filing shows a grant of 24,000 restricted stock units (RSUs) and a separate derivative award covering 144,000 shares (an option-style award), both reported at $0.00 per share. These are compensation awards rather than open-market purchases or sales.
Key Details
- Transaction date: April 1, 2026; Form 4 filed April 3, 2026 (timely filing).
- Awards: 24,000 RSUs (reported as A) and 144,000-share derivative award (reported as A); reported dollar amount $0.00.
- Vesting (footnotes): RSUs—25% vest June 5, 2027, remainder in 12 equal quarterly installments thereafter (F1). Option award—25% vests April 1, 2027, remainder in 36 equal monthly installments thereafter (F2).
- Shares owned after the transaction: Not specified in the provided filing excerpt.
- No indication this was a sale, purchase, 10b5-1 plan, or tax-withholding event in the provided data.
Context These awards are standard equity compensation intended to align executive incentives with shareholder value; they do not represent an immediate cash investment or sale. The RSUs convert to actual shares upon vesting; the derivative award appears to be an option-like grant that becomes exercisable per the vesting schedule. Such grants are common and should be interpreted as compensation rather than a direct bullish or bearish trading signal.
Insider Transaction Report
- Award
Common Stock
[F1]2026-04-01+24,000→ 211,375 total - Award
Stock Option (Right to Buy)
[F2]2026-04-01+144,000→ 144,000 totalExercise: $1.34Exp: 2036-03-31→ Common Stock (144,000 underlying)
Footnotes (2)
- [F1]These shares represent restricted stock units ("RSUs"). 25% of the RSUs shall vest on June 5, 2027, with the remainder vesting in 12 equal quarterly installments thereafter, subject to the Reporting Person's continued service with the Issuer on each such vesting date.
- [F2]25% of the shares subject to this option shall vest and become exercisable on April 1, 2027, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service with the Issuer on each such vesting date.